fbpx
 
Home / News, Videos & Publications / News / Medical Research /

BGU Alzheimer’s Researcher Demonstrates Specific Immune Response to Vaccine

BGU Alzheimer’s Researcher Demonstrates Specific Immune Response to Vaccine

September 21, 2009

Medical Research, Press Releases

BEER-SHEVA — September, 21 2009 — A researcher who is working on a vaccine for Alzheimer’s disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer’s patients.

This continuing research could one day lead to specific Alzheimer’s vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

Amyloid beta-peptide accumulates in the brain of AD patients where it appears to promote neuronal damage. In the new article published in the Journal of Immunology, BGU researcher Dr. Alon Monsonego determined that introducing A-beta into the brain triggers a natural immune response which can be detected in humans.

Importantly, the research team showed that the specificity and magnitude of this body response to A-beta depends on certain key genes of the immune system, which are highly polymorphic in the population (this means that except for identical twins, almost each of us has a different combination of genes termed “HLA alleles”).

Furthermore, this research combined humans and humanized mouse models. “We began with characterizing the genes in humans and then did the same study in mice, an unusual approach,” Monsonego explains.

“We then generated a humanized mouse model of AD, with a specific gene that was present in approximately 30 percent of our study group (HLA DR15 allele).

Conceivably, those people that have this gene could receive the same vaccine which will teach a person’s immune system to better fight the disease.”

Monsonego continues, “As in other mouse models of the disease, we show that with aging A-beta aggregates accumulate in brain areas of cognitive functions and stimulate an inflammatory reaction in the brain.

However, stimulating an immune response to A-beta in these humanized mice not only resulted in a highly efficient clearance of A-beta (plaque) from the brain, but also in a markedly reduced inflammatory reaction.

Furthermore, we were able to predict that the characteristics of immune response in mice were the same as in the humans.

“This study thus provides the basis for developing an individual-based (personalized medicine) immunotherapeutic approach to Alzheimer’s disease since different populations will respond differently to a vaccine based on their genetic background,” Monsonego explains.

“Now that we’ve proven we can anticipate the specific responses for several abundant genes in the population, further study is needed to ensure safety and efficacy in our humanized mouse model of AD.”

Dr. Monsonego, who holds the Zehava and Chezy Vered Career Development Chair for the Study of Alzheimer’s and Neurodegenerative Diseases, is a member of BGU’s Shraga Segal Department of Microbiology and Immunology and the National Institute for Biotechnology in the Negev.

The research is funded in part by the Israel Science Foundation, the Alzheimer Association and by the New York real estate developer Leonard Litwin and the Aaron Gural family.

“It is so rewarding to see how donors of American Associates, Ben-Gurion University of the Negev are contributing to the groundbreaking progress on discovering a viable Alzheimer’s vaccine,” states Executive Vice President Doron Krakow. “It’s another example of how BGU’s research helps people around the world.”

Dr. Alon Monsonego will be the guest speaker at a benefit for Alzheimer’s research in New York on October 28. For details, call 212-687-7721 ext. 186 or register Online.

ABOUT AMERICANS FOR BEN-GURION UNIVERSITY

By supporting a world-class academic institution that not only nurtures the Negev, but also shares its expertise locally and globally, Americans for Ben-Gurion University engages a community of Americans who are committed to improving the world. David Ben-Gurion envisioned that Israel’s future would be forged in the Negev. The cutting-edge research carried out at Ben-Gurion University drives that vision by sustaining a desert Silicon Valley, with the “Stanford of the Negev” at its center. The Americans for Ben-Gurion University movement supports a 21st century unifying vision for Israel by rallying around BGU’s remarkable work and role as an apolitical beacon of light in the Negev desert.

About Ben-Gurion University of the Negev

Ben-Gurion University of the Negev embraces the endless potential we have as individuals and as a commonality to adapt and to thrive in changing environments. Inspired by our location in the desert, we aim to discover, to create, and to develop solutions to dynamic challenges, to pose questions that have yet to be asked, and to push beyond the boundaries of the commonly accepted and possible.

We are proud to be a central force for inclusion, diversity and innovation in Israel, and we strive to extend the Negev’s potential and our entrepreneurial spirit throughout the world. For example, the multi-disciplinary School for Sustainability and Climate Change at BGU leverages over 50 years of expertise on living and thriving in the desert into scalable solutions for people everywhere.

BGU at a glance:  

20,000 students | 800 senior faculty | 3 campuses | 6 faculties: humanities & social sciences, health sciences, engineering sciences, natural sciences, business & management, and desert research.

 

For all press inquiries, please contact:

James Fattal, J Cubed Communications

516.289.1496

[email protected]